Action
Anticonvulsant, sodium channel blocker, glutamate release inhibitor (phenytoin pro-drug)

Status
FDA approved for seizures. Phase III stroke trial complete. Preliminary results: no significant differences between placebo (n=229) and fosphenytoin (n=233) in primary or secondary endpoints at 3 months. Results unpublished as of 1/2002.

Trial(s)
  = Ongoing
  = Completed

Fosphenytoin Phase 3

Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Fosphenytoin in Patients with Acute Ischemic Stroke

UID: 23